-
公开(公告)号：US10391058B2
公开(公告)日：2019-08-27
申请号：US15529101
申请日：2015-11-24
Applicant: NANOBIOTIX
Inventor： Matthieu Germain , Marie-Edith Meyre , Agnes Pottier , Laurent Levy
IPC: A61K9/127 , A61K9/51 , A61K9/00 , A61K31/704
Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm. The absolute surface charge value of a first biocompatible nanoparticle is of at least |10 mV| and the absolute surface charge value of the second biocompatible nanoparticle, or of any additional biocompatible nanoparticle, has a difference of at least 10 mV with the absolute surface charge value of the first biocompatible nanoparticle.
-
公开(公告)号：US08845507B2
公开(公告)日：2014-09-30
申请号：US12994162
申请日：2009-06-04
Applicant: Laurent Levy , Agnes Pottier , Annabelle Rouet , Julie Marill , Corinne Devaux , Matthieu Germain
Inventor： Laurent Levy , Agnes Pottier , Annabelle Rouet , Julie Marill , Corinne Devaux , Matthieu Germain
CPC classification number: A61K41/0038 , B82Y5/00 , Y10S977/904
Abstract: The present application relates to novel excitable particles which can be used in the health sector. It more particularly relates to particles which can generate electrons and/or high energy photon when excited by ionizing radiations such as X-Rays, γ-Rays, radioactive isotope and/or electron beams, and to the uses thereof in health, in particular in human health. The inventive particles are made of an inorganic material comprising oxygen, in particular an oxide, said material having an adequate density, and can be activated in vitro, ex vivo, or in vivo, by controllable external excitation, in order to disturb, alter or destroy target cells, tissues or organs. The invention also relates to methods for the production of said particles, and to pharmaceutical or medical device compositions containing same.
Abstract translation: 本申请涉及可用于健康部门的新型可兴奋颗粒。 更具体地说，涉及当通过诸如X射线，γ射线，放射性同位素和/或电子束的电离辐射激发时可以产生电子和/或高能光子的颗粒，以及其在健康中的用途，特别是在 人类健康。 本发明的颗粒由包含氧，特别是氧化物的无机材料制成，所述材料具有足够的密度，并且可以通过可控外部激发在体外，离体或体内活化，以便干扰，改变或 破坏靶细胞，组织或器官。 本发明还涉及生产所述颗粒的方法以及含有该颗粒的药物或医疗装置组合物。
-
公开(公告)号：US20240000940A1
公开(公告)日：2024-01-04
申请号：US18039728
申请日：2021-11-30
Applicant: NANOBIOTIX S.A.
Inventor： LAURENT LEVY , CÉLINE BERJAUD , ALEXANDRA MADEIRA , JULIE MARILL , MARIE-EDITH MEYRE
CPC classification number: A61K41/0038 , A61P35/00 , A61N5/1001 , A61K33/42 , B82Y5/00 , A61N2005/1098
Abstract: The invention concerns a particle and a composition comprising particles and their use in oncology. Specifically, the particles are porous, high-Z and carbon-free particles having internal pores, of longest dimension of at least 0.5 nm, and are for use in altering or destroying target cells in a mammal when said cells are exposed to ionizing radiation.
The present invention also provides a porous, high-Z and carbon-free particle wherein at least part of the porous structure of the particle is occupied by at least one therapeutic agent which is preferably for use in oncology.-
公开(公告)号：US11471482B2
公开(公告)日：2022-10-18
申请号：US16955096
申请日：2018-12-18
Applicant: NANOBIOTIX S.A.
Inventor： Agnès Pottier , Laurent Levy , Marie-Edith Meyre
IPC: A61K9/51 , A61K33/242 , A61K9/00 , A61K33/243 , B82Y5/00
Abstract: The present invention relates to the medical field, in particular to the enhancement of brain performances and for the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above (200), and an insulator material with a dielectric constant εijk equal to or below (100). It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source such as a light source, a magnetic field, or an ultrasound source.
-
5.发明授权公开(公告)号：US11020480B2
公开(公告)日：2021-06-01
申请号：US16129851
申请日：2018-09-13
Applicant: NANOBIOTIX
Inventor： Elsa Borghi , Laurent Levy , Agnes Pottier
Abstract: The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.
-
Patent Agency Ranking
公开(公告)号：US20210015756A1
公开(公告)日：2021-01-21
申请号：US16955092
申请日：2018-12-18
Applicant: NANOBIOTIX
Inventor： MARIE-EDITH MEYRE , LAURENT LEVY , AGNÈS POTTIER
Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above 200, and an insulator material with a dielectric constant εijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source.
-
公开(公告)号：US10391174B2
公开(公告)日：2019-08-27
申请号：US15635252
申请日：2017-06-28
Applicant: NANOBIOTIX
Inventor： Laurent Levy , Agnes Pottier , Laurence Poul , Laurence Maggiorella
Abstract: The present application relates to activatable nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cells, tissues or organs. It more particularly relates to nanoparticles which can generate a significantly efficient therapeutic effect, when exposed to ionizing radiations. The inventive nanoparticle is a metallic nanoparticle having, as the largest size, a size comprised between about 80 and 105 nm, the metal having preferably an atomic number (Z) of at least 25. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.
-
公开(公告)号：US20230211175A1
公开(公告)日：2023-07-06
申请号：US17927372
申请日：2021-05-25
Applicant: NANOBIOTIX S.A.
Inventor： ELSA BORGHI , LAURENT LEVY
CPC classification number: A61N5/10 , B82Y5/00 , A61K33/24 , A61P35/00 , A61K45/06 , A61N2005/1087 , A61N2005/1098
Abstract: The present disclosure offers therapeutic solutions to cancer patients up to now considered as unable to undergo a standard-of-care treatment involving radiotherapy or at high risk to undergo a standard-of-care treatment involving radiotherapy. The disclosure relates to nanoparticles and/or aggregates of nanoparticles for use in the treatment of cancer in such a patient, wherein the nanoparticles and/or aggregates of nanoparticles preferably comprise more than 30% by weight of at least one chemical element having an atomic number (Z) between 20 and 83. The disclosed treatments involve a step of administering the nanoparticles and/or aggregates of nanoparticles to the patient, and a step of exposing the patient to a total dose of ionizing radiations that is equal to or less than 85% of the total dose delivered in the standard-of-care treatment. The present description also discloses new compositions comprising such nanoparticles and/or aggregates of nanoparticles as well as uses thereof.
-
公开(公告)号：US11497717B2
公开(公告)日：2022-11-15
申请号：US16955092
申请日：2018-12-18
Applicant: NANOBIOTIX S.A.
Inventor： Marie-Edith Meyre , Laurent Levy , Agnès Pottier
Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above 200, and an insulator material with a dielectric constant εijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source.
-
公开(公告)号：US11229705B2
公开(公告)日：2022-01-25
申请号：US16472216
申请日：2017-12-19
Applicant: NANOBIOTIX
Inventor： Agnès Pottier , Laurent Levy , Marie-Edith Meyre
Abstract: The present invention relates to the medical field, in particular to the modulation of electrical polarization of neurons. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use for modulating electrical polarization of neurons in a subject, for example for use in prevention or treatment of a neuronal disease in a subject, typically by modulating electrical polarization of neurons in the subject, wherein i) when the nanoparticle or nanoparticles' aggregate is exposed to a light source, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling opto-electric transduction, opto-thermal transduction or opto-optical transduction, ii) when the nanoparticle or nanoparticles' aggregate is exposed to a magnetic field, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling magneto-electric transduction or magneto-thermal transduction, iii) when the nanoparticle or nanoparticles' aggregate's surface is exposed to an ultrasound source, the nanoparticle's or nanoparticles' aggregate's material is a material enabling acousto-electric transduction, and wherein the nanoparticle or nanoparticles' aggregate is either neutrally charged in the absence of any coating or is coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticles' aggregate. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.
-
-
-
-
-
-
-
-
-
Search Results
35
records
(took 0.021 seconds)
